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ABSTRACT 
Physical inactivity has been shown to be correlated to various disease and conditions.  Therefore, there is 
interest in the genetic mechanisms that control daily physical activity. Vivo-morpholinos are a new 
molecular biology tool that allows for the transient silencing of specific genes in an animal model, thereby 
allowing for a systematic method to turn off potential candidate genes involved in the regulation of 
physical activity.  Vivo-morpholinos have not been shown to be effective at silencing genes in the brain 
due to the fact that the vivo-morpholino cannot cross the blood brain barrier.   To counteract this, a tail 
vein injection (55 ul total volume; 11mg/kg vivo-morpholino;  6.5ug/kg RMP7) was given on three 
consecutive days containing the bradykinin analog RMP7 and a vivo-morpholino targeting Vmat2 to male 
C57/LJ mice (n=6). RMP7 has been shown to increase blood brain barrier permeability while Vmat2 is a 
dopamine transporter and is thought to be involved in the regulation of voluntary physical activity. 
Control animals received either RMP7 plus saline (n=6) or RMP7 plus a vivo-morpholino “scramble” 
control (n=6).  Physical activity was measured by wheel running. Results showed there was not a 
significant (p=0.24) knockdown in Vmat2 in the brain with RMP7 administration as compared to control 
animals. Interestingly there was a significant (p=0.001) knockdown in daily physical activity in the Vmat2 
treated animals compared to the control group.   RMP7 may still be a viable option for vivo-morpholino 
delivery in the brain; however an increased dosage may be required.  
